Seeing the Finish Line: Can Baseline OCT Values Predict Long-term Disability and Therapeutic Management in Multiple Sclerosis?

Multiple sclerosis (MS) exhibits heterogeneity in its clinical course, making it difficult for patients and their physicians to forecast the disease course and to make personal and therapeutic decisions. Validating biomarkers to aid disease prognosis would further help personalize MS care. Yet, only a few biomarkers such as brain and spinal cord MRI or oligoclonal bands have been validated.1,2 Considering that the retina is part of the gray matter of the CNS and is accessible to laser technologies such as optical coherence tomography (OCT), the studies of how MS damages the retina have provided significant insights into the disease course. Thus, retina-based biomarkers are being actively pursued to develop personalized medicine for people with MS (e.g., through the International Multiple Sclerosis Visual System Consortium [IMSVISUAL] collaboration3).

Read article at journal's website

Related Articles


Your email address will not be published.